{"url_path":"/sec/alec/8-k/2026-07-08/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 Termination of a Material Definitive Agreement.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1653087/0001193125-26-298526-index.html","accession_number":"0001193125-26-298526","cik":"0001653087","ticker":"ALEC","issuer_name":"Alector, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1653087/0001193125-26-298526-index.html","primary_entity_key":"0001653087","primary_entity_name":"Alector, Inc."},"word_count":413,"has_tables":true,"body_markdown":"## Item 1.02 Termination of a Material Definitive Agreement.\n\nAlector, Inc. (the “Company”) was developing the investigational progranulin-elevating monoclonal antibodies, latozinemab and nivisnebart, in collaboration with Glaxo Wellcome UK Limited (“GSK”), under the Collaboration and License Agreement between the parties, dated as of July 1, 2021, and as amended on May 19, 2023 (the “GSK Agreement”). On October 21, 2025, the Company announced that the Phase 3 INFRONT-3 clinical trial evaluating latozinemab in individuals with frontotemporal dementia due to a progranulin gene mutation did not meet its clinical co-primary endpoint. On April 29, 2026, the Company announced the discontinuation of the Phase 2 PROGRESS-AD trial of nivisnebart in individuals with early Alzheimer’s disease following an interim futility analysis. On July 6, 2026, GSK provided written notice to the Company terminating the GSK Agreement (“Notice”). Under the terms of the GSK Agreement, the termination will be effective 180 days from the Notice, or January 2, 2027.\n\n \n\nOn July 8, 2026, the Company repaid in full and terminated the Loan and Security Agreement, dated as of November 14, 2024, as amended (the “Loan Agreement”), by and among the Company, Alector LLC, a Delaware limited liability company, as co-borrower (together with the Company, the “Borrowers”), the several banks and other financial institutions or entities from time to time parties thereto, as lenders (collectively, referred to as the “Lenders”), and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the Lenders (“Hercules”). The Company repaid a total of $10,428,827.77 aggregate principal amount of outstanding loans, plus accrued interest and end of term and prepayment charges thereon.\n\nThe foregoing descriptions of the GSK Agreement and the Loan Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the GSK Agreement, a copy of which is filed as Exhibits 10.12 and 10.13 to the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and the Loan Agreement, a copy of which is filed as Exhibits 10.16 and 10.17, to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in each case incorporated by reference herein.\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nALECTOR, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJuly 8, 2026\n\nBy:\n\n/s/ Arnon Rosenthal\n\n \n\n \n\n \n\nArnon Rosenthal, Ph.D.\nCo-founder and Chief Executive Officer"}